Novartis Sees The Light And Plumps For Alcon Spin-Off
Having acquired Alcon for an eye-watering $52bn seven years ago, the Swiss major has decided that spinning off the eyecare business which has finally returned to growth (but is worth about half what Novartis paid in 2011) makes the most sense as it becomes a company even more focused on pharma.
You may also be interested in...
Narasimhan: Novartis' Specialized Portfolio Will Lead To Bigger Breakthroughs And Greater Value
At Novartis’s first R&D day since he took the helm, new CEO Vas Narasimhan told Scrip about how the company plans to build value through its newly acquired breakthrough technologies and what deals it is looking for next.
Device/Diagnostics Quarterly Dealmaking Statistics, Q2 2018
Second quarter device financing totaled $3.4 billion, less than half of the Q1 aggregate. Conversely, the $10.6 billion in device M&As was a 58% upsurge over the previous quarter. Like the device trends, total Q2 diagnostics financings (at $959 million) showed a 36% decline from Q1, while the $4.8 billion in M&A volume exhibited a significant increase over the previous quarter.
Novartis Blows Storm Clouds Off Sandoz US In Aurobindo Sale
Novartis's proposed sale of its generic oral solids portfolio – which has been battered by US price erosion – and the Sandoz US dermatology business to Aurobindo Pharma, in a deal potentially worth $1bn, allows the unit to finally concentrate on biosimilars, value-added medicines and complex generics.